https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=13700
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=13700
No pharmaceutical opinion available for this interaction.
Darunavir / cobicistat can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Buspirone.
–
–
–
Increased risk of CNS toxicity.
Risk of prolonged sedation and respiratory depression.
Use with caution the lowest effective dose and adjust according to clinical response and tolerance.
Monitor closely for adverse effects.
Or choose an alternative.
In patients already being treated with this combination and tolerating it, if deemed appropriate, keep actual treatment and exercise close monitoring of adverse effects and clinical effectiveness.
Lorazepam (Ativan), temazepam (Restoril), oxazepam (Serax).
Buspirone toxicity: impaired psychomotor performance, nausea, vomiting, dizziness, drowsiness, miosis, etc.
–
–
–